Merit Medical Systems has announced the launch of the proprietary Super HeRO and HeRO Ally products, additions to Merit’s expanding portfolio of dialysis access products.
These products are designed to assist clinicians in preserving existing fistulae or grafts that are in the process of failing because of central venous stenosis. These first-of-a-kind technologies expand upon the clinically-proven HeRO graft by allowing vascular surgeons to expand their repertoire of graft options to include early cannulation grafts to bypass central venous stenosis. By continuing to invest in innovative research and development in the field of dialysis, Merit continues to show its commitment to improving the clinical outcomes of dialysis patients.
“During the last several months, we have relocated manufacturing of the HeRO product line to our South Jordan facility, and now we have expanded options for physicians and patients,” said Fred P Lampropoulos, Merit’s chairman and chief executive officer.
The Super HeRO and HeRO Ally products are scheduled to be introduced in the United States over the next 30 days, with European release scheduled following receipt of the CE mark.